Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects with Advanced or Metastatic Clear-Cell Renal Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

Dendra Von Merveldt, R.N.
Phone: 214-645-8789

A Phase II Trial of High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy (SABR) for Patients with Metastatic Clear Cell Renal Cell Cancer (mRCC)

Hilda Benavides, R.N.
Phone: 214-633-1750